Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15579824 | 1.00 | GLP1R (0.59) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL15579832 | 1.00 | GLP1R (0.59) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL24983517 | 0.99 | GLP1R (0.60) | GLP1RNOD1FOLH1EPHX2 | |
| SCHEMBL18088441 | 0.94 | GLP1R (0.65) | GLP1RNOD1FOLH1 | |
| SCHEMBL16182607 | 0.94 | GLP1R (0.65) | GLP1RNOD1FOLH1 | |
| SCHEMBL16182606 | 0.94 | GLP1R (0.65) | GLP1RNOD1FOLH1 | |
| SCHEMBL12686635 | 0.94 | GLP1R (0.65) | GLP1RNOD1FOLH1 | |
| SCHEMBL12686659 | 0.94 | GLP1R (0.65) | GLP1RNOD1FOLH1 | |
| SCHEMBL22402567 | 0.94 | GLP1R (0.65) | GLP1RNOD1FOLH1 | |
| SCHEMBL13184651 | 0.94 | GLP1R (0.65) | GLP1RNOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023288019-A2 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20170008945-A1 | Novel Insulin Derivatives and the Medical Uses Hereof | NOVO NORDISK A/S (DK) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008945-A1 | Novel Insulin Derivatives and the Medical Uses Hereof | IAPP, INSR, GPR119 | GLP1R 13/4885NOD1 2884/4885FOLH1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.